Cost-effectiveness of tacrolimus ointment vs. standard treatment in patients with moderate and severe atopic dermatitis: A health-economic model simulation based on a patient survey and clinical trial data

British Journal of Dermatology

Volumn 156, Issue 5, 2007, Pages 913-921

  Hjelmgren, J ^a   Svensson, A ^b   Jorgensen E T ^c   Lindemalm Lundstam, B ^d   Ragnarson Tennvall, G ^a  

^a SWEDISH INSTITUTE FOR HEALTH ECONOMICS   (Sweden)

^b LUND UNIVERSITY HOSPITAL   (Sweden)

^c KALMAR COUNTY HOSPITAL   (Sweden)

^d Vastra Frolunda Hosp   (Sweden)

Author keywords

Atopic dermatitis; Cost effectiveness; Model simulation; Tacrolimus ointment

Indexed keywords

CORTICOSTEROID; HYDROCORTISONE BUTYRATE; TACROLIMUS;

ADULT; ARTICLE; ATOPIC DERMATITIS; CALCULATION; CLINICAL FEATURE; COMPARATIVE STUDY; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DISEASE SEVERITY; DRUG EFFICACY; FEMALE; HEALTH CARE COST; HEALTH CARE UTILIZATION; HEALTH ECONOMICS; HEALTH SURVEY; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; SENSITIVITY ANALYSIS; SIMULATION;

ADULT; COST-BENEFIT ANALYSIS; DERMATITIS, ATOPIC; FEMALE; HEALTH CARE COSTS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MARKOV CHAINS; MODELS, ECONOMIC; OINTMENTS; QUALITY-ADJUSTED LIFE YEARS; SWEDEN; TACROLIMUS;

EID: 34247325180     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2006.07707.x     Document Type: Article

References (17)

1. Kiebert G, Sorensen SV, Revicki D et al. Atopic dermatitis is associated with decrement in health-related quality of life. Int J Dermatol 2002 41:151 8.
2. Lamb SR, Rademaker M. Pharmacoeconomics of drug therapy for atopic dermatitis. Exper Opin Pharmacother 2002 3:249 55.
3. Ellis CN, Drake LA, Prendergast MM et al. Cost-effectiveness analysis of tacrolimus ointment versus high-potency topical corticosteroids in adults with moderate to severe atopic dermatitis. J Am Acad Dermatol 2003 48:553 63.
4. Abramovits W, Boguniewicz M, Paller AS et al. The economics of topical immunomodulators for the treatment of atopic dermatitis. Pharmacoeconomics 2005 23:543 66.
5. Reitamo S, Harper J, Bos JD et al. 0.03% tacrolimus ointment applied once or twice daily is more efficacious than 1% hydrocortisone acetate in children with moderate to severe atopic dermatitis: results of a randomized double-blind controlled trial. Br J Dermatol 2004 150:554 62.
6. Koo JYM, Fleischer Jr. AB, Abramovits W et al. Tacrolimus ointment is safe and effective in the treatment of atopic dermatitis: results in 8000 patients. J Am Acad Dermatol 2005 53:S195 205.
7. Hanifin JM, Ling MR, Langley R et al. Tacrolimus ointment for the treatment of atopic dermatitis in adult patients: part I, efficacy. J Am Acad Dermatol 2001 44:S28 38.
8. Briggs A, Sculpher M. An introduction to Markov modelling for economic evaluation. Pharmacoeconomics 1998 13:397 409.
9. Sonnenberg FA, Beck JR. Markov models in medical decision making: a practical guide. Med Decis Making 1993 13:322 38.
10. Läkemedelsförmånsnämnden. General Guidelines for Economic Evaluations from the Pharmaceutical Benefits Board, Vol. LFNAR 2003:2. Stockholm:The Pharmaceutical Benefits Board, 2003.
11. Reitamo S, Ortonne JP, Sand C et al. A multicentre, randomized, double-blind, controlled study of long-term treatment with 0.1% tacrolimus ointment in adults with moderate to severe atopic dermatitis. Br J Dermatol 2005 152:1282 9.
12. Hanifin JM, Rajka G. Diagnostic features of atopic dermatitis. Acta Derm Venereol (Stockh) 1980 92 (Suppl. 44 7.
13. Persson U, Hjelmgren J. Hälso- och sjukvården behöver kunskap om hur befolkningen värderar hälsan. Läkartidningen 2003 100:3436 7.
14. Annemans L, Genesté B, Jolain B. Early modelling for assessing health and economic outcomes of drug therapy. Value Health 2000 3:427 34.
15. Kjellgren KI, Ring L, Lindblad ÅK et al. To follow dermatology treatment regimens - patients' and providers' views. Acta Derm Venereol (Stockh) 2004 84:445 50.
16. Abramovits W, Boguniewicz M, Prendergast MM et al. Comparisons of efficacy and cost-effectiveness of topical immunomodulators in the management of atopic dermatitis. J Med Econ 2003 6:1 14.
17. Rawlins MD, Culyer AJ. National Institute for Clinical Excellence and its value judgements. BMJ 2004 329:224 27.